U.S. University Professor Recommends Promoting Vaping as a Harm Reduction Tool Worldwide

Today, on March 30, news reports that the Dean of the University of Michigan's School of Public Health and his team recently concluded that there is sufficient evidence to support that e-cigarettes can serve as a primary aid for adults to quit smoking. They recommend that the governments of the United States, Australia, and Canada, as well as professional medical teams, consider the potential of e-cigarettes in smoking cessation more seriously and reduce misconceptions about them. Additionally, several universities in Switzerland have used magnetic resonance imaging to find that nicotine e-cigarettes cause less damage to the lungs compared to traditional cigarettes.

The current public debate surrounding nicotine e-cigarettes mainly revolves around their risks to teenagers and their potential for helping adults quit smoking. Professor Kenneth Warner, Dean of the University of Michigan's School of Public Health, believes that promoting e-cigarettes as a harm reduction tool does not conflict with the goal of reducing youth e-cigarette use; the focus should be on effective government and media promotion. Professor Warner, along with colleagues from King's College London, Harvard University, and other institutions, co-authored an article titled "Nicotine e-cigarettes as a tool for smoking cessation," published in the medical journal Nature.

The paper points out that there is sufficient evidence indicating that e-cigarettes can be used as a primary aid for adults to quit smoking; however, very few members of the public and healthcare professionals recognize their potential value in harm reduction. Professor Warner's team took a global perspective, analyzing numerous countries that use e-cigarettes for smoking cessation and those that are smoke-free. They found that in the UK and New Zealand, e-cigarettes as a smoking cessation option received high levels of support and promotion, while in the US, Canada, and Australia, despite acknowledging the potential advantages of e-cigarettes, they do not receive effective recommendations from governments and healthcare institutions.

They also cited the FDA's (U.S. Food and Drug Administration) designation of certain e-cigarette brands as "appropriate for the protection of public health" as a listing standard, stating that this action "indirectly suggests that the FDA believes e-cigarettes can help some people quit smoking; otherwise, they would not do so."

Another study initiated by the University of Bern, the University of Zurich, and the University of Basel found that nicotine e-cigarettes can effectively promote lung perfusion and increase blood flow. Researchers used magnetic resonance imaging to monitor lung function in 44 healthy participants. The results showed that compared to normal conditions, tobacco users had significantly reduced lung perfusion/blood flow after smoking, while e-cigarette users experienced enhanced lung perfusion/blood flow after using nicotine e-cigarettes. Researchers believe this indicates that nicotine e-cigarettes do not suppress lung function like traditional cigarette smoke and demonstrate that nicotine e-cigarettes have a lesser impact on lung damage.

Both Professor Warner's and the Swiss universities' studies recognize the significant potential of e-cigarettes as a harm reduction tool. As Professor Warner stated in the paper, e-cigarettes are not a panacea for ending tobacco harm, but they can contribute to this noble public health goal.

References

Kenneth E. Warner, Neal L. Benowitz, Ann McNeill, et al. Nicotine e-cigarettes as a tool for smoking cessation. Nature Medicine, 2023

Sylvia Nyilas, Grzegorz Bauman, Insa Korten, et al. MRI Shows Lung Perfusion Changes after Vaping and Smoking. RSNA Radiology, 2022